Sobi is committed to providing you with ongoing support
Schedule a virtual discussion with a Gamifant Health Systems Director today.
Schedule a virtual discussion with a Gamifant Health Systems Director today.
You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
Preclinical data suggest that the cytokine IFNγ plays a central and upstream role in the pathogenesis of primary HLH. A massive overexpression of IFNγ leads directly to downstream hypercytokinemia and hyperinflammation.1,4,5
Read moreGamifant binds to soluble and receptor-bound forms of IFNγ. Binding to IFNγ neutralizes its activity, blocking its intracellular signaling to inhibit macrophage activation and the downstream release of proinflammatory cytokines.1,2,6,7
Read moreDepending on patient response, Gamifant can be incrementally titrated upward or downward. Similarly, the concomitant dose of dexamethasone may be tapered from the original starting dose according to the judgment of the treating physician.1
Read moreGamifant yielded a 63% overall response rate (ORR) in patients with refractory, recurrent, or progressive disease or intolerance to conventional therapy. Seventy percent of patients proceeded to transplant.1
See the data